

Supplementary Table S4. Patient disposition

MeDRA Preferred Term	Dose Escalation and Expansion Part I Cohorts (n=75)	Dose Expansion Part II Cohorts (n=97)	All Patients (N=172)
Discontinued study drug	75 (100)	97 (100)	172 (100)
Adverse event	1 (1)	2 (2)	3 (2)
Physician decision	0 (0)	1 (1)	1 (1)
Disease progression	71 (95)	93 (96)	164 (95)
Study terminated	1 (1)	0 (0)	1 (1)
Withdrawal by subject	2 (3)	1 (1)	3 (2)
Discontinued from study	75 (100)	97 (100)	172 (100)
Death	54 (72)	57 (59)	111 (65)
Lost to follow-up	0 (0)	3 (3)	3 (2)
Other	16 (21)	30 (31)	46 (27)
Study terminated	0 (0)	1 (1)	1 (1)
Withdrawal by subject	5 (7)	6 (6)	11 (6)